33 related articles for article (PubMed ID: 22168626)
1. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
Ham JM; Kim M; Kim T; Ryu SE; Park H
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
[TBL] [Abstract][Full Text] [Related]
2. A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.
Whittaker S; Ménard D; Kirk R; Ogilvie L; Hedley D; Zambon A; Lopes F; Preece N; Manne H; Rana S; Lambros M; Reis-Filho JS; Marais R; Springer CJ
Cancer Res; 2010 Oct; 70(20):8036-44. PubMed ID: 20807807
[TBL] [Abstract][Full Text] [Related]
3. Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie L; Hedley D; Takle AK; Wilson DM; Pons JF; Coulter T; Kirk R; Cantarino N; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2010 Sep; 18(18):6934-52. PubMed ID: 20667740
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic
Ye Q; Srivastava P; Al-Kuwari N; Chen X
Neural Regen Res; 2023 Jul; 18(7):1613-1622. PubMed ID: 36571370
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
Zhao Y; Bai L; Liu L; McEachern D; Stuckey JA; Meagher JL; Yang CY; Ran X; Zhou B; Hu Y; Li X; Wen B; Zhao T; Li S; Sun D; Wang S
J Med Chem; 2017 May; 60(9):3887-3901. PubMed ID: 28463487
[TBL] [Abstract][Full Text] [Related]
6. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells.
Chen Y; Sang Y; Li S; Xue J; Chen M; Hong S; Lv W; Sehgal K; Xiao H; Liu R
Transl Oncol; 2024 Jul; 45():101991. PubMed ID: 38728872
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Thieno[3,2-
La Monica G; Pizzolanti G; Baiamonte C; Bono A; Alamia F; Mingoia F; Lauria A; Martorana A
ACS Omega; 2023 Sep; 8(38):34640-34649. PubMed ID: 37779971
[TBL] [Abstract][Full Text] [Related]
8. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
Singh AK; Sonawane P; Kumar A; Singh H; Naumovich V; Pathak P; Grishina M; Khalilullah H; Jaremko M; Emwas AH; Verma A; Kumar P
ACS Omega; 2023 Aug; 8(31):27819-27844. PubMed ID: 37576670
[TBL] [Abstract][Full Text] [Related]
9. Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine-sulfonamide hybrids as selective BRAF
Singh AK; Novak J; Kumar A; Singh H; Thareja S; Pathak P; Grishina M; Verma A; Yadav JP; Khalilullah H; Pathania V; Nandanwar H; Jaremko M; Emwas AH; Kumar P
RSC Adv; 2022 Oct; 12(46):30181-30200. PubMed ID: 36329938
[TBL] [Abstract][Full Text] [Related]
10. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D; Ryan KR; Lakkaniga NR; Acharya B; Garcia NG; Smith EL; Frett B
J Med Chem; 2021 Aug; 64(16):11747-11773. PubMed ID: 34402300
[TBL] [Abstract][Full Text] [Related]
11. Structure property relationships of N-acylsulfonamides and related bioisosteres.
Francisco KR; Varricchio C; Paniak TJ; Kozlowski MC; Brancale A; Ballatore C
Eur J Med Chem; 2021 Jun; 218():113399. PubMed ID: 33823393
[TBL] [Abstract][Full Text] [Related]
12. Regioselective Synthesis of Functionalized 3- or 5-Fluoroalkyl Isoxazoles and Pyrazoles from Fluoroalkyl Ynones and Binucleophiles.
Chalyk BA; Khutorianskyi A; Lysenko A; Fil Y; Kuchkovska YO; Gavrilenko KS; Bakanovych I; Moroz YS; Gorlova AO; Grygorenko OO
J Org Chem; 2019 Dec; 84(23):15212-15225. PubMed ID: 31661620
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Evaluation of [
Jiang C; Xie L; Zhang Y; Fujinaga M; Mori W; Kurihara Y; Yamasaki T; Wang F; Zhang MR
Mol Imaging; 2018; 17():1536012118795952. PubMed ID: 30251592
[TBL] [Abstract][Full Text] [Related]
14. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
16. Hexachlorocyclotriphosphazene (HCCP)-mediated direct formation of thioethers and ethers from quinazolin-4(3H)-ones.
Hu B; Zhang X; Sheng L; Guo M; Shen Z; Hu X; Sun N; Mo W
Molecules; 2013 May; 18(5):5580-93. PubMed ID: 23676469
[TBL] [Abstract][Full Text] [Related]
17. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
Rowbottom MW; Faraoni R; Chao Q; Campbell BT; Lai AG; Setti E; Ezawa M; Sprankle KG; Abraham S; Tran L; Struss B; Gibney M; Armstrong RC; Gunawardane RN; Nepomuceno RR; Valenta I; Hua H; Gardner MF; Cramer MD; Gitnick D; Insko DE; Apuy JL; Jones-Bolin S; Ghose AK; Herbertz T; Ator MA; Dorsey BD; Ruggeri B; Williams M; Bhagwat S; James J; Holladay MW
J Med Chem; 2012 Feb; 55(3):1082-105. PubMed ID: 22168626
[TBL] [Abstract][Full Text] [Related]
18. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
James J; Ruggeri B; Armstrong RC; Rowbottom MW; Jones-Bolin S; Gunawardane RN; Dobrzanski P; Gardner MF; Zhao H; Cramer MD; Hunter K; Nepomuceno RR; Cheng M; Gitnick D; Yazdanian M; Insko DE; Ator MA; Apuy JL; Faraoni R; Dorsey BD; Williams M; Bhagwat SS; Holladay MW
Mol Cancer Ther; 2012 Apr; 11(4):930-41. PubMed ID: 22319199
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
